Companies
/Healthcare
Cencora Inc
$345.69
▼ $4.87 (−1.39%) today
Markets open · 10:57am ET
Cencora (COR) Earnings History & Trends
86%
EPS beat rate
+2.82%
Avg. EPS surprise
Consecutive EPS beats
COR vs Market · 30-day return after each reportCORS&P 500
COR EPS Trend · estimate vs actualEstimateActual
COR Revenue Trend · estimate vs actualEstimateActual
How Often Does Cencora Beat Earnings Estimates?
Cencora beat EPS estimates in 6 of its last 7 reported quarters, and has beaten 6 quarters in a row.
| Quarter | EPS · est. | Surprise | Revenue · est. | Surprise |
|---|---|---|---|---|
| Q4 2026 Adjusted EPS excludes Q4 items including $177.4 million of acquisition and divestiture-related deal and integration expenses, $116.0 million acquisition-related intangibles amortization, and tax discrete items. The tax items include an $87.1 million tax benefit related to the pending MWI Animal Health divestiture and a $146.8 million unfavorable Swiss deferred tax asset valuation adjustment. GAAP diluted EPS was $2.71. | $4.66 est. $4.57 | +1.88% | $88.4B est. $87.9B | +0.50% |
| Q3 2026 | $4.48 | — | $84.8B | — |
| Q2 2026 | $4.75 est. $4.73 | +0.48% | $78.4B est. $81.0B | −3.31% |
| Q1 2026 | $4.08 est. $4.04 | +0.99% | $85.9B est. $86.2B | −0.28% |
| Q4 2025 | $3.84 est. $3.79 | +1.44% | $83.7B est. $83.4B | +0.40% |
| Q3 2025 | $4.00 est. $3.84 | +4.23% | $80.7B est. $80.1B | +0.68% |
| Q2 2025 | $4.42 est. $4.10 | +7.92% | $75.5B est. $75.8B | −0.46% |
Figures from SEC filings and company reports. Not investment advice.